Werewolf differentiates through tumor-selective activation technology, aiming to achieve best-in-class tolerability profiles compared to conventional proinflammatory therapies. The company is advancing dual lead candidates (WTX-124 IL-2 and WTX-330 IL-12) through clinical development and actively seeking strategic partnerships for further development.
Cyborg Score Rationale
The company demonstrates promising clinical data with unprecedented response rates and favorable tolerability, supported by recent FDA Fast Track designation for WTX-124. However, it faces significant challenges including micro-cap market position (~$30M), recent analyst downgrades citing capital needs, and dependency on strategic partnerships to advance pipeline programs.
Top Insights
WTX-124 Phase 1b data showed 30% overall response rate as monotherapy in post-checkpoint inhibitor melanoma with potential best-in-class tolerability
Recent December 2025 pipeline update reveals company seeking strategic partnerships and shifting focus to novel INDUCER T cell engager platform alongside INDUKINE programs
Company received FDA Fast Track designation for WTX-124 in October 2025, accelerating potential development pathway for lead oncology candidate
Received Nasdaq minimum bid price notice in February 2026, indicating stock price pressure and potential delisting risk if price doesn't recover above $1.00
Named Competitors
Yescarta/Tecartus — CAR-T cell therapies for hematologic malignancies